Advertisement

Prevention of CINV in Patients Receiving High-Dose Multiple-Day Chemotherapy

  • Luigi CelioEmail author
Chapter

Abstract

High-dose chemotherapy involves the administration of potentially toxic doses of chemotherapeutic agents in an effort to eradicate cancer cells. A wide range of high-dose regimens has been developed and they typically consist of several agents given at high doses over 2–7 days. The use of peripheral blood as a source of stem cells for autologous hematopoietic stem-cell transplantation (HSCT) greatly contributed to the application of myeloablative chemotherapy in the treatment of both hematological and solid malignancies. In the setting of HSCT, chemotherapy-induced nausea and vomiting (CINV) are almost universal and may occur not only during administration of anticancer agents but also for days or weeks during the recovery period from chemotherapy. In addition, irradiation used in many preparative regimens is associated with a number of acute side effects that include nausea and vomiting, compounding the side effects of chemotherapy. Therefore, high-dose multiple-day chemotherapy with HSCT provides a unique challenge to achieving good antiemetic control and remains one of the neglected areas of antiemetic research. There are difficulties in developing evidenced-based recommendations for the optimal strategy of CINV control in this setting. The chapter provides an overview of CINV in patients undergoing high-dose chemotherapy regimens, with a focus on challenges and unmet needs in this special population. It also provides an overview of the results with modern antiemetics in this setting. Finally, current treatment guidelines are also discussed along with suggestions for future investigations.

Keywords

CINV High-dose chemotherapy NK-1 receptor antagonist Palonosetron Aprepitant Stem-cell transplantation 

References

  1. 1.
    Aschan J (2007) Risk assessment in haematopoietic stem cell transplantation: conditioning. Best Pract Res Clin Haematol 20:295–310CrossRefPubMedGoogle Scholar
  2. 2.
    Schwartzberg LS, Jacobs P, Matsuoka P et al (2012) The role of second-generation 5-HT3 receptor antagonists in managing chemotherapy-induced nausea and vomiting in haematological malignancies. Crit Rev Oncol Hematol 83:59–70CrossRefPubMedGoogle Scholar
  3. 3.
    Selle F, Gligorov J, Richard S et al (2015) Intensive chemotherapy as salvage treatment for solid tumors: focus on germ cell cancer. Braz J Med Biol Res 48:13–24PubMedCentralCrossRefPubMedGoogle Scholar
  4. 4.
    Appelbaum FR (2007) Hematopoietic-cell transplantation at 50. N Engl J Med 357:1472–1475CrossRefPubMedGoogle Scholar
  5. 5.
    Holtik U, Albrecht M, Chemnitz JM et al (2014) Bone marrow versus peripheral blood allogenic haematopoietic stem cell transplantation for haematological malignancies in adults. Cochrane Database Syst Rev. doi: 10.1002/14651858.CD010189.pub2 Google Scholar
  6. 6.
    Rolling C, Knop S, Bornhauser M (2014) Multiple myeloma. Lancet. doi: 10.1016/S0140-673(14)60493-1 Google Scholar
  7. 7.
    Hagemeister FB (2002) Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue. Cancer Chemother Pharmacol 49(Suppl 1):S13–S20CrossRefPubMedGoogle Scholar
  8. 8.
    Bastos DA, Feldman DR (2014) The role of high-dose chemotherapy in the management of germ cell tumors. Curr Opin Oncol 26:284–293CrossRefPubMedGoogle Scholar
  9. 9.
    Hesketh PJ (2008) Chemotherapy-induced nausea and vomiting. N Engl J Med 358:2482–2494CrossRefPubMedGoogle Scholar
  10. 10.
    Perez EA, Tiemeier T, Solberg LA (1999) Antiemetic therapy for high-dose chemotherapy with transplantation: report of a retrospective analysis of a 5-HT3 regimen and literature review. Support Care Cancer 7:413–424CrossRefPubMedGoogle Scholar
  11. 11.
    Fetting JH, Grochow LB, Folstein MF et al (1982) The course of nausea and vomiting after high-dose cyclophosphamide. Cancer Treat Rep 66:1487–1493PubMedGoogle Scholar
  12. 12.
    Antman K, Eder JP, Elias A et al (1987) High-dose combination alkylating agent preparative regimen with autologous bone marrow support: the Dana-Farber Cancer Institute/Beth Israel Hospital experience. Cancer Treat Rep 71:119–125PubMedGoogle Scholar
  13. 13.
    Trigg ME, Inverso DM (2008) Nausea and vomiting with high-dose chemotherapy and stem cell rescue therapy: a review of antiemetic regimens. Bone Marrow Transplant 42:501–506CrossRefPubMedGoogle Scholar
  14. 14.
    Spitzer TR, Grunberg SM, Dicato MA (1998) Antiemetic strategies for high-dose chemoradiotherapy-induced nausea and vomiting. Support Care Cancer 6:233–236CrossRefPubMedGoogle Scholar
  15. 15.
    Einhorn LH, Grunberg SM, Rapoport B et al (2011) Antiemetic therapy for multiple-day chemotherapy and additional topics consisting of rescue antiemetics and high-dose chemotherapy with stem cell transplant: review and consensus statement. Support Care Cancer 19(suppl 1):S1–S4CrossRefPubMedGoogle Scholar
  16. 16.
    Jimenez JL, Martin-Ballesteros E, Sureda A et al (2006) Chemotherapy-induced nausea and vomiting in acute leukemia and stem cell transplant patients: results of a multicenter, observational study. Haematologica 91:84–91Google Scholar
  17. 17.
    Adel NG, Khan A, Lucarelli C (2006) Use of palonosetron 0.25 mg IV daily and incidence of nausea and vomiting in patients undergoing bone marrow transplantation. In: 2006 ASCO annual meeting proceedings part I. J Clin Oncol 24:664sGoogle Scholar
  18. 18.
    De Mulder PHM, Roila F, Kris MG et al (1998) Consensus regarding multiple day and rescue antiemetic therapy. Support Care Cancer 6:248–252CrossRefPubMedGoogle Scholar
  19. 19.
    Stroncek DF, Fautsch SK, Lasky LC et al (1991) Adverse reactions in patients transfused with cryopreserved marrow. Transfusion 31:521–526CrossRefPubMedGoogle Scholar
  20. 20.
    del Giglio A, Soares HP, Caparroz C et al (2000) Granisetron is equivalent to ondansetron for prophylaxis of chemotherapy-induced nausea and vomiting: results of a meta-analysis of randomized controlled trials. Cancer 89:2301–2308CrossRefPubMedGoogle Scholar
  21. 21.
    Jordan K, Hinke A, Grothey A et al (2005) Granisetron versus tropisetron for prophylaxis of acute chemotherapy-induced emesis: a pooled analysis. Support Care Cancer 13:26–31CrossRefPubMedGoogle Scholar
  22. 22.
    Slaby J, Trneny M, Prochazka B et al (2000) Antiemetic efficacy of three serotonin antagonists during high-dose chemotherapy and autologous stem cell transplantation in malignant lymphoma. Neoplasma 47:319–322PubMedGoogle Scholar
  23. 23.
    Fox-Geiman MP, Fisher SG, Kiley K et al (2001) Double-blind comparative trial of oral ondansetron versus oral granisetron versus IV ondansetron in the prevention of nausea and vomiting associated with highly emetogenic preparative regimens prior to stem cell transplantation. Biol Blood Marrow Transplant 7:596–603CrossRefPubMedGoogle Scholar
  24. 24.
    Matsuoka S, Okamoto S, Watanabe R et al (2003) Granisetron plus dexamethasone versus granisetron alone in the prevention of vomiting induced by conditioning for stem cell transplantation: a prospective randomized study. Int J Hematol 77:86–90CrossRefPubMedGoogle Scholar
  25. 25.
    Walsh T, Morris AK, Holle LM et al (2004) Granisetron vs ondansetron for the prevention of nausea and vomiting in hematopoietic stem cell transplant patients: results of a prospective, double-blind, randomized trial. Bone Marrow Transplant 34:963–968CrossRefPubMedGoogle Scholar
  26. 26.
    Aapro MS, Grunberg SM, Manikhas GM et al (2006) A phase III, double-blind, randomized trial of palonosetron compared with ondansetron in preventing chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy. Ann Oncol 17:1441–1449CrossRefPubMedGoogle Scholar
  27. 27.
    Saito M, Aogi K, Sekine I et al (2009) Palonosetron plus dexamethasone versus granisetron plus dexamethasone for prevention of nausea and vomiting during chemotherapy: a double-blind, double-dummy, randomized, comparative phase III trial. Lancet Oncol 10:115–124CrossRefPubMedGoogle Scholar
  28. 28.
    Celio L, Frustaci S, Denaro A et al (2011) Palonosetron in combination with 1-day versus 3-day dexamethasone for prevention of nausea and vomiting following moderately emetogenic chemotherapy: a randomized, multicenter, phase III trial. Support Care Cancer 19:1217–1225PubMedCentralCrossRefPubMedGoogle Scholar
  29. 29.
    Rojas C, Stathis M, Thomas AG et al (2008) Palonosetron exhibits unique molecular interactions with the 5-HT3 receptor. Anesth Analg 107:469–478CrossRefPubMedGoogle Scholar
  30. 30.
    Rojas C, Thomas AG, Alt J et al (2010) Palonosetron triggers 5-HT(3) receptor internalization and causes prolonged inhibition of receptor function. Eur J Pharmacol 626:193–199CrossRefPubMedGoogle Scholar
  31. 31.
    Rojas C, Li Y, Zhang J et al (2010) The antiemetic 5-HT3 receptor antagonist palonosetron inhibits substance P-mediated responses in vitro and in vivo. J Pharmacol Exp Ther 335:362–368PubMedCentralCrossRefPubMedGoogle Scholar
  32. 32.
    Marcacci G, Becchimanzi C, Arcamone M et al (2009) Single vs double dose palonosetron for the prevention of acute and delayed nausea and vomiting in patients undergoing high-dose chemotherapy and autologous stem cell transplantation. In: Joint ECCO 15-34th ESMO Mulidisciplinary Congress Berlin, 20–24 September 2009, Abstract Book. Eur J Cancer 7:574Google Scholar
  33. 33.
    Rzepecki P, Pielichowski W, Oborska S et al (2009) Palonosetron in prevention of nausea and vomiting after highly emetogenic chemotherapy before haematopoietic stem cell transplantation – single center experience. Transplant Proc 41:3247–3249CrossRefPubMedGoogle Scholar
  34. 34.
    Ripaldi M, Parasole R, De Simone G et al (2010) Palonosetron to prevent nausea and vomiting in children undergoing BMT: efficacy and safety. Bone Marrow Transplant 45:1663–1664CrossRefPubMedGoogle Scholar
  35. 35.
    Mattiuzzi GN, Cortes JE, Blamble DA et al (2010) Daily palonosetron is superior to ondansetron in the prevention of delayed chemotherapy-induced nausea and vomiting in patients with acute myelogenous leukemia. Cancer 116:5659–5666PubMedCentralCrossRefPubMedGoogle Scholar
  36. 36.
    Musso M, Scalone R, Crescimanno A et al (2010) Palonosetron and dexamethasone for prevention of nausea and vomiting in patients receiving high-dose chemotherapy with auto-SCT. Bone Marrow Transplant 45:123–127CrossRefPubMedGoogle Scholar
  37. 37.
    Giralt SA, Mangan KF, Maziarz RT et al (2011) Three palonosetron regimens to prevent CINV in myeloma patients receiving multiple-day high-dose melphalan and hematopoietic stem cell transplantation. Ann Oncol 22:939–946CrossRefPubMedGoogle Scholar
  38. 38.
    Mirabile A, Celio L, Magni M et al (2014) Evaluation of an every-other-day palonosetron schedule to control emesis in multiple-day high-dose chemotherapy. Future Oncol 10:2569–2578CrossRefPubMedGoogle Scholar
  39. 39.
    Yeh SP, Lo WC, Hsieh CY et al (2014) Palonosetron and dexamethasone for the prevention of nausea and vomiting in patients receiving allogeneic hematopoietic stem cell transplantation. Support Care Cancer 22:1199–1206CrossRefPubMedGoogle Scholar
  40. 40.
    Chou CW, Chen YK, Yu YB et al (2014) Palonosetron versus first-generation 5-hydroxytryptamine type 3 receptor antagonists for emesis prophylaxis in patients undergoing allogeneic hematopoietic stem cell transplantation. Ann Hematol 93:1225–1232CrossRefPubMedGoogle Scholar
  41. 41.
    Hesketh PJ, Grunberg SM, Gralla RJ et al (2003) The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin – The Aprepitant Protocol 052 Study Group. J Clin Oncol 21:4112–4119CrossRefPubMedGoogle Scholar
  42. 42.
    Schmoll HJ, Aapro MS, Poli-Bigelli S et al (2006) Comparison of an aprepitant regimen with a multiple-day ondansetron regimen, both with dexamethasone, for antiemetic efficacy in high-dose cisplatin treatment. Ann Oncol 17:1000–1006CrossRefPubMedGoogle Scholar
  43. 43.
    Aapro MS, Walko CM (2010) Aprepitant: drug-drug interactions in perspective. Ann Oncol 21:2316–2323CrossRefPubMedGoogle Scholar
  44. 44.
    Bubalo JS, Cherala G, McCune J et al (2012) Aprepitant pharmacokinetics and assessing the impact of aprepitant on cyclophosphamide metabolism in cancer patients undergoing hematopoietic stem cell transplantation. J Clin Pharmacol 52:586–594CrossRefPubMedGoogle Scholar
  45. 45.
    Egerer G, Eisenlohr K, Gronkowski M et al (2010) The NK1 receptor antagonist aprepitant does not alter the pharmacokinetics of high-dose melphalan chemotherapy in patients with multiple myeloma. Br J Clin Pharmacol 70:903–907PubMedCentralCrossRefPubMedGoogle Scholar
  46. 46.
    Paul B, Trovato JA, Thompson J et al (2010) Efficacy of aprepitant in patients receiving high-dose chemotherapy with hematopoietic stem cell support. J Clin Pharm Pract 16:45–51Google Scholar
  47. 47.
    Jordan K, Jahn F, Jahn P et al (2011) The NK-1 receptor-antagonist aprepitant in high-dose chemotherapy (high-dose melphalan and high-dose T-ICE: paclitaxel, ifosfamide, carboplatin, etoposide): efficacy and safety of a triple antiemetic combination. Bone Marrow Transplant 46:784–789CrossRefPubMedGoogle Scholar
  48. 48.
    Pielichowski W, Barzal J, Gawronski K et al (2011) A triple-drug combination to prevent nausea and vomiting following BEAM chemotherapy before autologous hematopoietic stem cell transplantation. Transplant Proc 43:3107–3110CrossRefPubMedGoogle Scholar
  49. 49.
    Pielichowski W, Gawronski K, Mlot B et al (2011) Triple-drug combination in the prevention of nausea and vomiting following busulfan plus cyclophosphamide chemotherapy before allogeneic hematopoietic stem cell transplantation. J Buon 16:541–546PubMedGoogle Scholar
  50. 50.
    Uchida M, Ikesue H, Miyamoto T et al (2013) Effectiveness and safety of antiemetic aprepitant in Japanese patients receiving high-dose chemotherapy prior to autologous hematopoietic stem cell transplantation. Biol Pharm Bull 36:819–824CrossRefPubMedGoogle Scholar
  51. 51.
    Uchida M, Kato K, Ikesue H et al (2013) Efficacy and safety of aprepitant in allogeneic hematopoietic stem cell transplantation. Pharmacotherapy 33:893–901PubMedCentralCrossRefPubMedGoogle Scholar
  52. 52.
    Stiff PJ, Fox-Geiman MP, Kiley K et al (2013) Prevention of nausea and vomiting associated with stem cell transplant: results of a prospective, randomized trial of aprepitant used with highly emetogenic preparative regimens. Biol Blood Marrow Transplant 19:49–55CrossRefPubMedGoogle Scholar
  53. 53.
    Deauna-Limayo D, Aljitawi OS, Ganguly S et al (2013) Combined use of multiday palonosetron with aprepitant and low-dose dexamethasone in prevention of nausea and emesis among patients with multiple myeloma and lymphoma undergoing autologous hematopoietic stem cell transplant: a pilot study. J Oncol Pharm Pract 20:263–269CrossRefPubMedGoogle Scholar
  54. 54.
    Sakurai M, Mori T, Kato J et al (2014) Efficacy of aprepitant in preventing nausea and vomiting due to high-dose melphalan-based conditioning for allogeneic hematopoietic stem cell transplantation. Int J Hematol 99:457–462CrossRefPubMedGoogle Scholar
  55. 55.
    Schmitt T, Goldschmidt H, Neben K et al (2014) Aprepitant, granisetron, and dexamethasone for prevention of chemotherapy-induced nausea and vomiting after high-dose melphalan in autologous transplantation for multiple myeloma: results of a randomized, placebo-controlled phase III trial. J Clin Oncol 32:3413–3420CrossRefPubMedGoogle Scholar
  56. 56.
    Olver I, Molassiotis A, Aapro M et al (2011) Antiemetic research: future directions. Support Care Cancer 19(Suppl 1):S49–S55CrossRefPubMedGoogle Scholar
  57. 57.
    Roila F, Herrstedt J, Aapro M et al (2010) Guideline update for MASCC and ESMO in the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting: results of the Perugia consensus conference. Ann Oncol 21(Suppl 5):v232–v243CrossRefPubMedGoogle Scholar
  58. 58.
    Basch E, Prestrud AA, Hesketh PJ et al (2011) Antiemetics: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol 29:4189–4198CrossRefPubMedGoogle Scholar
  59. 59.
    Boccia RV, Gordan LN, Clark G et al (2011) Efficacy and tolerability of transdermal granisetron for the control of chemotherapy-induced nausea and vomiting associated with moderately and highly multi-day chemotherapy: a randomized, double-blind, phase III study. Support Care Cancer 19:1609–1617PubMedCentralCrossRefPubMedGoogle Scholar
  60. 60.
    Celio L, Ricchini F, De Braud F (2013) Efficacy, safety, and patient acceptability of single-dose fosaprepitant regimen for the prevention of chemotherapy-induced nausea and vomiting. Patient Prefer Adherence 7:391–400PubMedCentralCrossRefPubMedGoogle Scholar
  61. 61.
    Navari RM (2013) Management of chemotherapy-induced nausea and vomiting. Drugs 73:249–262CrossRefPubMedGoogle Scholar
  62. 62.
    Celio L, Aapro M (2013) Research on chemotherapy-induced nausea: back to the past for an unmeet need? J Clin Oncol 31:1376–1377CrossRefPubMedGoogle Scholar
  63. 63.
    Navari RM, Gray SE, Kerr AC (2011) Olanzapine versus aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a randomized phase III trial. J Support Oncol 9:188–195CrossRefPubMedGoogle Scholar
  64. 64.
    Navari RM, Nagy CK, Gray SE (2013) Olanzapine versus metoclopramide for the treatment of breakthrough chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic chemotherapy. Support Care Cancer 21:1655–1663CrossRefPubMedGoogle Scholar
  65. 65.
    Abe M, Hirashima Y, Kasamatsu Y et al (2015) Efficacy and safety of olanzapine combined with aprepitant, palonosetron, and dexamethasone for preventing nausea and vomiting induced by cisplatin-based chemotherapy in gynecological cancer: KCOG-G1301 phase II trial. Support Care Cancer. doi: 10.1007/s00520-015-2829-z Google Scholar

Copyright information

© Springer International Publishing Switzerland 2016

Authors and Affiliations

  1. 1.Department of Medical Oncology 1Fondazione IRCCS Istituto Nazionale TumoriMilanItaly

Personalised recommendations